Evidence map›Paper›PMID 28210556›Full record

ReviewGland surgery2017

Are breast cancer stem cells the key to resolving clinical issues in breast cancer therapy?

Hidetaka Shima, Akimitsu Yamada, Takashi Ishikawa, Itaru Endo

Open access · diamondAbstract readReview
In one paragraph

Review in Gland surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Frontiers in oncology · 2024
    Article
  7. Frontiers in pharmacology · 2024
    Article
  8. Article
  9. Review
  10. Review
  11. Targeting Breast Cancer Stem Cells.International journal of biological sciences · 2023
    Review
  12. Article
  13. Metabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. International journal of molecular sciences · 2020
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hidetaka ShimaDepartment of Gastroenterological Surgery, Yokohama City University, Yokohama, Kanagawa 236-0004, Japan.
Akimitsu YamadaDepartment of Gastroenterological Surgery, Yokohama City University, Yokohama, Kanagawa 236-0004, Japan.
Takashi IshikawaDepartment of Breast disease, Tokyo Medical University Hospital, Tokyo 160-0023, Japan.
Itaru EndoDepartment of Gastroenterological Surgery, Yokohama City University, Yokohama, Kanagawa 236-0004, Japan.
Yokohama City University · JPTokyo Medical University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the dramatic advances in breast cancer treatment over the past two decades, it is still the most common malignancies in women. One of the reasons patients succumb to breast cancer is treatment resistance leading to metastasis and recurrence. Recently, cancer stem cells (CSCs) have been suggested as a cause of metastasis and recurrence in several cancers because of their unique characteristics, including self-renewal, pluripotency, and high proliferative ability. Increasing evidence has implicated breast cancer stem cells (BCSCs) as essential for tumor development, progression, recurrence, and treatment resistance. BCSCs exhibit resistance to treatment owing to several inter-related factors, including overexpression of ATP-binding cassette (ABC) transporters and increased aldehyde dehydrogenase (ALDH) activity, DNA repair, and reactive oxygen species (ROS) scavenging. In addition, the Notch, Hedgehog, and Wnt signaling pathways have been suggested as the major pathways involved in the self-renewal and differentiation of BCSCs. Despite growing evidence suggesting the importance of BCSCs in progression and metastasis, clear criteria for the identification of BCSCs in clinical practice have yet to be established. Several potential markers have been suggested, including CD44

Indexed as

aldehyde dehydrogenase 1 (ALDH1)Breast cancercancer stem cell (CSC)therapy resistance

Identifiers

PMID28210556
PMCPMC5293654
OpenAlexW2522486308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.